Coronary Artery Disease
Conditions
Interventions
Control Group:Conventional post-PCI treatment
Exposure group:Conventional post-PCI treatment + Yiqi Huoxue Chinese Herbal Medicine
Exposure group:Routine post-PCI treatment for coronary artery + qi-invigorating and blood-activating Chinese herbal medicine (1 year)
High-Exposure Group:Routine post-PCI treatment for coronary artery disease plus qi-invigorating and blood-activating Chinese herbal medicine (2 years).
Sponsors
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1)Surgical indications compliant with PCI. According to the requirements for selecting revascularization strategies in the "Chinese Percutaneous Coronary Intervention Guidelines (2016)": - Stable coronary artery disease: The degree of coronary artery lesion diameter stenosis is used as the basis for decision-making on whether to intervene. Lesions with a diameter stenosis of =90% can be directly intervened. When the diameter stenosis is <90%, intervention is recommended only for lesions with corresponding ischemic evidence or a fractional flow reserve (FFR) =0.8. - Non-ST-segment elevation acute coronary syndrome: Patients' history, symptoms, signs, electrocardiogram, and troponin are used as tools for risk stratification. The Global Registry of Acute Coronary Events (GRACE) risk score is used for ischemic risk stratification to select revascularization strategies. - Acute ST-segment elevation myocardial infarction: Minimizing time delays is the critical issue in implementing reperfusion therapy for acute ST-segment elevation myocardial infarction. Patients should be treated with PCI as soon as possible. For patients with multivessel disease, intervention is performed only on the infarct-related artery, except in cases of combined cardiogenic shock or persistent ischemic signs after PCI. 2) 18 years = age = 80 years, gender.
Exclusion criteria
Exclusion criteria: 1) Pregnant/lactating women; 2) Participants in other drug trials within 3 months; 3) Patients with mental disorders, alcoholism, or substance abuse; 4) Type 1 diabetes or poorly controlled Type 2 diabetes (fasting blood glucose >11mmol/L) with complications; 5) Gastrointestinal disorders/surgeries affecting drug absorption; 6) Organ dysfunction: Chronic renal insufficiency (creatinine >ULN), chronic liver dysfunction (ALT/AST >3×ULN), active/recurrent peptic ulcers, malignancies, hematological diseases; 7) Allergy to Chinese herbal medicines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Angina Symptom Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome Scale Score; | — |
Countries
China
Contacts
Public ContactLi Yunlun
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Outcome results
None listed